.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J07B_ViralVaccines.J07BN02_Covid19ViralVectorNonRep.Covid19ViralVectorNonRep .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J07B_ViralVaccines.J07BN02_Covid19ViralVectorNonRep.Covid19ViralVectorNonRep| name: | Covid19ViralVectorNonReplicating | |
| ATC code: | J07BN02 | route: | intramuscular |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
COVID-19 vaccines of the viral vector, non-replicating type (e.g., ChAdOx1 nCoV-19/AstraZeneca and Ad26.COV2.S/Johnson & Johnson) use non-replicating adenovirus vectors to deliver genetic material encoding SARS-CoV-2 spike protein. These vaccines are used for prevention of COVID-19 and are authorized for emergency or standard use in many countries worldwide.
No formal pharmacokinetic (PK) studies are conducted for non-replicating viral vector COVID-19 vaccines in humans, as traditional PK parameters do not apply to vaccines. Estimated values based on typical administration to healthy adults.